Highlights Swedish Orphan Biovitrum AB

Equities

SOBI

SE0000872095

Market Closed - Nasdaq Stockholm Other stock markets 11:29:55 2024-06-07 am EDT			5-day change	1st Jan Change
281 ^SEK	-2.63%		-0.50%	+5.24%

May. 28	BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB	CI
May. 24	Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB	May. 28	CI
Sobi Finalizes Inaugural SEK3 Billion Bond Issue	May. 08	MT
Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy	May. 08	MT
Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug	Apr. 26	MT
Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A	Apr. 26	CI
Sobi's SEK10 Billion Note Program Gets Regulatory Nod in Sweden	Apr. 26	MT
Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Swedish Orphan Biovitrum AB Provides Earnings Guidance for 2024	Apr. 25	CI
Sobi to Expand in South Korea via Rare Disease JV with Handok	Feb. 13	MT
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	Feb. 12	MT
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	Feb. 12	CI
Sobi's Growth Potential Remains 'Tremendous' Amid Conservative FY24 Outlook, RBC Says	Feb. 09	MT
Swedish Orphan Biovitrum AB Provides Revenue Guidance for the Year 2024	Feb. 08	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 08	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Sobi's Profit to Get Royalty Boost as Sanofi Partnerships Outperform, RBC Says	Feb. 02	MT
Swedish Orphan Biovitrum Completes Issuance, Repurchase of Convertible Shares	Nov. 01	MT
Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Publ.) Enter into Amendment No. 1 to the License and Development Agreement	23-10-31	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30	CI
Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G	23-10-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Swedish Orphan Biovitrum AB

Equities

SOBI

SE0000872095

Highlights

Filters